S&P 500   4,191.98
DOW   33,426.63
QQQ   336.51
Mount Etna volcano erupts, raining ash on Catania, forcing flight suspension at local airport
Central Bank: “Final stage” beginning now (Ad)
China tells tech manufacturers to stop using Micron chips, stepping up feud with United States
Stock market today: Asian shares mostly rise despite worries about US debt talks
Is This The End Of Your Retirement? (Ad)
SpaceX launches two Saudi astronauts on private flight to space station
Civil rights groups warn tourists about Florida in wake of 'hostile' laws
Is This The End Of Your Retirement? (Ad)
South Korean, German leaders agree to cooperate on supply chains, North Korea
Animal rights activists protest octopus farm plans in Spain
S&P 500   4,191.98
DOW   33,426.63
QQQ   336.51
Mount Etna volcano erupts, raining ash on Catania, forcing flight suspension at local airport
Central Bank: “Final stage” beginning now (Ad)
China tells tech manufacturers to stop using Micron chips, stepping up feud with United States
Stock market today: Asian shares mostly rise despite worries about US debt talks
Is This The End Of Your Retirement? (Ad)
SpaceX launches two Saudi astronauts on private flight to space station
Civil rights groups warn tourists about Florida in wake of 'hostile' laws
Is This The End Of Your Retirement? (Ad)
South Korean, German leaders agree to cooperate on supply chains, North Korea
Animal rights activists protest octopus farm plans in Spain
S&P 500   4,191.98
DOW   33,426.63
QQQ   336.51
Mount Etna volcano erupts, raining ash on Catania, forcing flight suspension at local airport
Central Bank: “Final stage” beginning now (Ad)
China tells tech manufacturers to stop using Micron chips, stepping up feud with United States
Stock market today: Asian shares mostly rise despite worries about US debt talks
Is This The End Of Your Retirement? (Ad)
SpaceX launches two Saudi astronauts on private flight to space station
Civil rights groups warn tourists about Florida in wake of 'hostile' laws
Is This The End Of Your Retirement? (Ad)
South Korean, German leaders agree to cooperate on supply chains, North Korea
Animal rights activists protest octopus farm plans in Spain
S&P 500   4,191.98
DOW   33,426.63
QQQ   336.51
Mount Etna volcano erupts, raining ash on Catania, forcing flight suspension at local airport
Central Bank: “Final stage” beginning now (Ad)
China tells tech manufacturers to stop using Micron chips, stepping up feud with United States
Stock market today: Asian shares mostly rise despite worries about US debt talks
Is This The End Of Your Retirement? (Ad)
SpaceX launches two Saudi astronauts on private flight to space station
Civil rights groups warn tourists about Florida in wake of 'hostile' laws
Is This The End Of Your Retirement? (Ad)
South Korean, German leaders agree to cooperate on supply chains, North Korea
Animal rights activists protest octopus farm plans in Spain

Novartis (NVS) Stock Forecast, Price & News

$100.81
+0.46 (+0.46%)
(As of 05/19/2023 08:48 PM ET)
Compare
Today's Range
$99.98
$101.00
50-Day Range
$81.61
$104.91
52-Week Range
$74.09
$105.56
Volume
1.53 million shs
Average Volume
2.12 million shs
Market Capitalization
$213.68 billion
P/E Ratio
31.02
Dividend Yield
2.25%
Price Target
$82.25

Novartis MarketRank™ Forecast

Analyst Rating
Hold
2.09 Rating Score
Upside/​Downside
18.4% Downside
$82.25 Price Target
Short Interest
Healthy
0.24% of Float Sold Short
Dividend Strength
Moderate
Based on Four Factors
Sustainability
N/A
News Sentiment
0.33mentions of Novartis in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
8.25%
From $6.67 to $7.22 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.88 out of 5 stars

Medical Sector

666th out of 971 stocks

Pharmaceutical Preparations Industry

331st out of 476 stocks


NVS stock logo

About Novartis (NYSE:NVS) Stock

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Receive NVS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Novartis and its competitors with MarketBeat's FREE daily newsletter.

NVS Stock News Headlines

Pharma Giants Novartis, Lilly, Merck, and Novo Outperform Market (NVS)
Big pharma stocks Novartis, Eli Lilly, Merck, and Novo Nordisk are outperforming the market, driven by successful drugs and strong earnings growth.
Why Legend Biotech Stock Is Having Its Best Month Yet (NVS)
With the biotech market’s focus back on treatments for cancer and other life-threatening diseases, Legend has now tripled off its bottom to a record high.
AI Creates New Cancer Drug - In Just 30 Days!
On December 22, 2022, AI discovered a new treatment for multiple myeloma... in just 4 months... On March 19, 2023, AI discovered a new drug for liver cancer... in only 30 days... There's one small-cap at the center of it all. Bill Gates owns 7 million shares... Billionaire hedge-fund manager Steve Cohen owns 1.4 million shares...
Brokerages Set Novartis AG (NYSE:NVS) PT at $84.40
Buy THIS stock before Taiwan is attacked
... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.
Bank of America Securities Remains a Buy on Novartis (NVS)
Novartis AG (NYSE:NVS) Sees Significant Drop in Short Interest
Is This Big Pharma Stock a Buy for Dividend Investors?
Novartis: Valuation Seems Fair
Why Novartis Stock Is Trading Higher Today
Novartis (NVS) Scheduled to Post Quarterly Earnings on Tuesday
See More Headlines
Receive NVS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Novartis and its competitors with MarketBeat's FREE daily newsletter.

NVS Company Calendar

Ex-Dividend for 3/20 Dividend
3/09/2023
Dividend Payable
3/20/2023
Last Earnings
4/25/2023
Today
5/22/2023
Next Earnings (Estimated)
7/18/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Employees
101,703
Year Founded
1996

Price Target and Rating

Average Stock Price Forecast
$82.25
High Stock Price Forecast
$90.00
Low Stock Price Forecast
$70.00
Forecasted Upside/Downside
-18.4%
Consensus Rating
Hold
Rating Score (0-4)
2.09
Research Coverage
11 Analysts

Profitability

Net Income
$6.96 billion
Pretax Margin
16.56%

Debt

Sales & Book Value

Annual Sales
$50.55 billion
Cash Flow
$6.33 per share
Book Value
$24.60 per share

Miscellaneous

Outstanding Shares
2,119,600,000
Free Float
2,119,388,000
Market Cap
$213.68 billion
Optionable
Optionable
Beta
0.54

Social Links


Key Executives

  • Vasant Narasimhan
    Chief Executive Officer
  • Steffen Lang
    President-Operations
  • Harry Werner Kirsch
    Chief Financial Officer
  • Shreeram Aradhye
    Chief Medical Officer
  • Klaus Moosmayer
    Chief Ethics, Risk & Compliance Officer













NVS Stock - Frequently Asked Questions

Should I buy or sell Novartis stock right now?

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novartis in the last twelve months. There are currently 2 sell ratings, 6 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" NVS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NVS, but not buy additional shares or sell existing shares.
View NVS analyst ratings
or view top-rated stocks.

What is Novartis' stock price forecast for 2023?

11 equities research analysts have issued 12 month target prices for Novartis' stock. Their NVS share price forecasts range from $70.00 to $90.00. On average, they expect the company's stock price to reach $82.25 in the next year. This suggests that the stock has a possible downside of 18.4%.
View analysts price targets for NVS
or view top-rated stocks among Wall Street analysts.

How have NVS shares performed in 2023?

Novartis' stock was trading at $90.72 at the beginning of 2023. Since then, NVS stock has increased by 11.1% and is now trading at $100.81.
View the best growth stocks for 2023 here
.

Are investors shorting Novartis?

Novartis saw a drop in short interest in April. As of April 15th, there was short interest totaling 5,500,000 shares, a drop of 13.1% from the March 31st total of 6,330,000 shares. Based on an average trading volume of 2,210,000 shares, the short-interest ratio is presently 2.5 days. Approximately 0.3% of the shares of the stock are sold short.
View Novartis' Short Interest
.

When is Novartis' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, July 18th 2023.
View our NVS earnings forecast
.

How were Novartis' earnings last quarter?

Novartis AG (NYSE:NVS) issued its quarterly earnings results on Tuesday, April, 25th. The company reported $1.71 earnings per share for the quarter, beating analysts' consensus estimates of $1.55 by $0.16. The firm earned $12.95 billion during the quarter, compared to the consensus estimate of $12.60 billion. Novartis had a net margin of 13.78% and a trailing twelve-month return on equity of 23.29%. Novartis's revenue for the quarter was up 3.4% on a year-over-year basis. During the same period in the previous year, the business posted $1.46 earnings per share.

How often does Novartis pay dividends? What is the dividend yield for Novartis?

Novartis announced an annual dividend on Thursday, February 2nd. Shareholders of record on Friday, March 10th will be given a dividend of $3.4694 per share on Monday, March 20th. This represents a dividend yield of 2.6%. The ex-dividend date of this dividend is Thursday, March 9th. This is a positive change from the stock's previous annual dividend of $1.18.
Read our dividend analysis for NVS
.

Is Novartis a good dividend stock?

Novartis (NYSE:NVS) pays an annual dividend of $2.27 per share and currently has a dividend yield of 2.27%. The company has been increasing its dividend for 4 consecutive year(s), indicating that it does not yet have a strong track record of dividend growth. The dividend payout ratio is 69.85%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, NVS will have a dividend payout ratio of 31.44% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for NVS.

What is Vas Narasimhan's approval rating as Novartis' CEO?

938 employees have rated Novartis Chief Executive Officer Vas Narasimhan on Glassdoor.com. Vas Narasimhan has an approval rating of 95% among the company's employees. This puts Vas Narasimhan in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Novartis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Novartis investors own include Johnson & Johnson (JNJ), Pfizer (PFE), AbbVie (ABBV), Intel (INTC), AT&T (T), Walt Disney (DIS), Gilead Sciences (GILD), Cisco Systems (CSCO), Merck & Co., Inc. (MRK) and NVIDIA (NVDA).

What is Novartis' stock symbol?

Novartis trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVS."

Who are Novartis' major shareholders?

Novartis' stock is owned by a number of institutional and retail investors. Top institutional investors include Dodge & Cox (0.96%), Envestnet Asset Management Inc. (0.40%), Bank of America Corp DE (0.36%), Franklin Resources Inc. (0.33%), Dimensional Fund Advisors LP (0.29%) and Charles Schwab Investment Management Inc. (0.21%).

How do I buy shares of Novartis?

Shares of NVS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Novartis' stock price today?

One share of NVS stock can currently be purchased for approximately $100.81.

How much money does Novartis make?

Novartis (NYSE:NVS) has a market capitalization of $213.68 billion and generates $50.55 billion in revenue each year. The company earns $6.96 billion in net income (profit) each year or $3.25 on an earnings per share basis.

How many employees does Novartis have?

The company employs 101,703 workers across the globe.

Does Novartis have any subsidiaries?
The following companies are subsidiares of Novartis: 1 A Pharma GmbH, Abadia Retuerta S.A, Admune Therapeutics, Advanced Accelerator Applications, Advanced Accelerator Applications, Advanced Accelerator Applications International SA, Advanced Accelerator Applications S.A., Advanced Accelerator Applications S.r.l., Advanced Accelerator Applications USA Inc., Aeropharm GmbH, Alcon, Alcon – Couvreur NV, Amblyotech, Amblyotech Inc., Arctos Medical, Arctos Medical AG, Australia Pty Ltd, Beijing Novartis Pharma Co. Ltd., BioMedical Research Co. Ltd., CELLforCURE, Cadent Therapeutics, Cadent Therapeutics Cambridge, Cellerys, Cellerys AG, CellforCure, Chiron Corporation, Ciba-Geigy Japan Limited, Co. Ltd, CoStim Pharmaceuticals, CoStim Pharmaceuticals Inc., Coalesce Product Development Limited, Corthera, Development Co. Ltd., EBEWE Pharma Ges.m.b.H Nfg. KG, Encore Vision, Endocyte, Endocyte Inc., Eon Labs Inc., Farmanova Saglik Hizmetleri Ltd, Fougera Pharmaceuticals, Fougera Pharmaceuticals Inc, Gyroscope Therapeutics, HEXAL AG, Hexal, IDB Holland BV, Iberica S.L.U., Ilaçlari Sanayi ve Ticaret A.S, JSC Sandoz, Japat AG, Kedalion Therapeutics Inc., Lek Pharmaceuticals d.d., Lek S.A., Manufacturing Pte Ltd , Navigate BioPharma Services Inc, Neutec Pharma Limited, Novartis (Hellas) S.A.C.I., Novartis (Singapore) Pte Ltd, Novartis (Taiwan) Co. Ltd, Novartis (Thailand) Limited, Novartis Argentina S.A., Novartis Australia Pty Ltd, Novartis Austria GmbH, Novartis Biociências S.A., Novartis Biosciences Perú S.A., Novartis Bioventures AG, Novartis Business Services GmbH, Novartis Capital Corporation, Novartis Chile S.A., Novartis Corporation, Novartis Corporation Sdn. Bhd., Novartis Deutschland GmbH, Novartis Ecuador S.A., Novartis Farma S.p.A., Novartis Farma – Produtos Farmacêuticos S.A., Novartis Farmacéutica S.A, Novartis Farmacéutica S.A. de C.V., Novartis Finance Corporation, Novartis Finance S.A., Novartis Finance Services Ltd, Novartis Finland Oy Espoo, Novartis Gene Therapies, Novartis Gene Therapies EU Limited, Novartis Gene Therapies Inc., Novartis Grimsby Limited, Novartis Groupe France S.A., Novartis Healthcare A/S, Novartis Healthcare Philippines Inc., Novartis Healthcare Private Limited, Novartis Holding AG, Novartis Hungary Healthcare Limited Liability Company, Novartis India Limited, Novartis Inflammasome Research, Novartis Integrated Services Limited, Novartis International AG, Novartis International Pharmaceutical Investment AG, Novartis Investment Ltd, Novartis Investments S.à r.l., Novartis Ireland Limited, Novartis Israel Ltd, Novartis Korea Ltd., Novartis Middle East FZE, Novartis Netherlands B.V., Novartis Neva LLC, Novartis New Zealand Ltd, Novartis Norge AS, Novartis Ophthalmics AG, Novartis Optogenetics Research Inc., Novartis Overseas Investments AG, Novartis Pharma (Logistics) Inc., Novartis Pharma (Pakistan) Limited, Novartis Pharma AG, Novartis Pharma B.V. , Novartis Pharma GmbH, Novartis Pharma GmbH, Novartis Pharma K.K., Novartis Pharma LLC, Novartis Pharma Maroc SA, Novartis Pharma NV, Novartis Pharma Produktions GmbH, Novartis Pharma S.A.E., Novartis Pharma S.A.S., Novartis Pharma Schweiz AG, Novartis Pharma Schweizerhalle AG, Novartis Pharma Services AG, Novartis Pharma Services Romania S.R.L., Novartis Pharma Stein AG, Novartis Pharmaceuticals Canada Inc., Novartis Pharmaceuticals Corporation, Novartis Pharmaceuticals Limited, Novartis Pharmaceuticals UK Limited, Novartis Poland Sp. z o.o., Novartis Portugal S.G.P.S. Lda., Novartis Ringaskiddy Limited, Novartis Saglik Gida ve Tarim Ürünleri Sanayi ve Ticaret A.S, Novartis Saudi Ltd., Novartis Securities Investment Ltd, Novartis Services Inc., Novartis Slovakia s.r.o., Novartis South Africa (Pty) Ltd, Novartis Sverige AB, Novartis UK Limited, Novartis US Foundation, Novartis Vaccines and Diagnostics Inc, Novartis Vietnam Company Limited, Novartis de Colombia S.A., Novartis de Venezuela S.A., Novartis s.r.o., Oriel Therapeutics Inc., PT. Novartis Indonesia, Protez Pharmaceuticals, Pte Ltd, Research Inc, Salutas Pharma GmbH, Sandoz A/S, Sandoz AG, Sandoz B.V., Sandoz Canada Inc., Sandoz Egypt Pharma S.A.E., Sandoz Farmacéutica S.A., Sandoz Farmacêutica Lda., Sandoz GmbH, Sandoz Hungary Limited Liability Company, Sandoz Ilaç Sanayi ve Ticaret A.S., Sandoz Inc, Sandoz Industrial Products S.A, Sandoz International GmbH, Sandoz K.K., Sandoz Limited, Sandoz Manufacturing Inc., Sandoz NV, Sandoz Pharma K.K, Sandoz Pharmaceuticals AG, Sandoz Pharmaceuticals d.d., Sandoz Philippines Corporation, Sandoz Polska Sp. z o.o. , Sandoz Private Limited, Sandoz Pty Ltd, Sandoz S.A. de C.V, Sandoz S.A.S., Sandoz S.R.L., Sandoz S.p.A., Sandoz South Africa (Pty) Ltd, Sandoz Ukraine LLC, Sandoz d.o.o. farmaceutska industrija, Sandoz do Brasil Indústria Farmacêutica Ltda, Sandoz s.r.o., Selexys Pharmaceuticals Corporation, Shanghai Novartis Trading Ltd., Société par actions SANDOZ, Spinifex Pharmaceuticals, The Medicines Company, The Medicines Company, Triangle International Reinsurance Limited, Trinity River Insurance Co Ltd, Vedere Bio, Vedere Bio ll, Xiidra, Ziarco, and Ziarco Group Limited.
Read More
How can I contact Novartis?

Novartis' mailing address is LICHTSTRASSE 35, BASEL V8, CH 4056. The official website for the company is www.novartis.com. The company can be reached via phone at (161) 324-1111, via email at investor.relations@novartis.com, or via fax at 41-61-324-7826.

This page (NYSE:NVS) was last updated on 5/22/2023 by MarketBeat.com Staff

My Account -